Interestingly, in 2007 the US Food and Drug Administration approved anti-C5 blocking therapies for treating paroxysmal nocturnal hemoglobinuria and more recently for atypical hemolytic uremic syndrome [41,42]. Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.